Related Experiment Video

Updated: Jan 5, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.5K

Macrophage miR-34a Is a Key Regulator of Cholesterol Efflux and Atherosclerosis

Yanyong Xu1, Yang Xu1, Yingdong Zhu1

  • 1Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, OH, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|October 13, 2019
PubMed

Insights

MicroRNA-34a (miR-34a) regulates macrophage cholesterol transport and inflammation, key factors in atherosclerosis. Inhibiting miR-34a reduces atherosclerosis development and promotes regression, offering a potential therapeutic target for cardiometabolic diseases.

Area of Science:

  • Molecular Biology
  • Cardiovascular Research
  • Metabolic Diseases

Background:

  • Macrophages are critical in atherosclerosis pathogenesis.
  • Molecular mechanisms regulating macrophage function in atherosclerosis are not fully understood.

Purpose of the Study:

  • To investigate the role of microRNA-34a (miR-34a) in macrophage cholesterol metabolism and atherosclerosis.
  • To explore miR-34a's impact on macrophage polarization and intestinal lipid absorption.

Main Methods:

  • Investigated miR-34a's regulation of ATP-binding cassette transporters (ABCA1, ABCG1) in macrophages.
  • Assessed miR-34a's effect on macrophage polarization via liver X receptor α.
  • Examined miR-34a's influence on intestinal cholesterol absorption by inhibiting CYP7A1 and CYP8B1.
  • Utilized macrophage-selective and global miR-34a ablation models in atherosclerosis studies.
  • Evaluated therapeutic inhibition of miR-34a for atherosclerosis regression and metabolic disorder reversal.

Main Results:

  • miR-34a modulates macrophage cholesterol efflux and reverse cholesterol transport by regulating ABCA1 and ABCG1.
  • miR-34a influences M1/M2 macrophage polarization through liver X receptor α.
  • Loss of miR-34a decreases intestinal cholesterol/fat absorption by inhibiting CYP7A1 and CYP8B1.
  • Ablation of miR-34a significantly inhibits atherosclerosis development.
  • Therapeutic inhibition of miR-34a promotes atherosclerosis regression and reverses metabolic disorders.

Conclusions:

  • miR-34a is a central regulator of macrophage cholesterol efflux, inflammation, and atherosclerosis.
  • Targeting miR-34a presents a promising therapeutic strategy for cardiometabolic diseases.
Keywords:
ABCA1ABCG1LXRatherosclerosischolesterol effluxinflammationmiR-34a

More Related Videos

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay08:18

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

Published on: January 7, 2019

9.5K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.0K

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.2K
Inflammation01:38

Inflammation

Overview
61.4K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
287
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
730